Japan suspends two vaccines after infant deaths (Update)

Mar 07, 2011

Japan's health ministry has suspended two widely-used vaccines made by drugs giants Pfizer and Sanofi-Aventis as it investigates whether they are linked to the recent deaths of four infants.

The infants, aged from around six months to under two years old, died over a three-day period this month after receiving the vaccinations or in combination with other drugs, the health ministry said in a statement.

The two drugs -- used to prevent forms of pneumonia and meningitis -- are Prevenar made by New York-based Pfizer and ActHIB, a drug made by the Sanofi Pasteur wing of Paris-headquartered Sanofi-Aventis.

Sanofi's ActHIB is used in over 120 countries, according to the company.

The two vaccines have been administered to an estimated 1.5 million children in Japan, the ministry said.

There have been no reports so far from the doctors who treated the children that establish a causal relationship between the vaccines and their deaths, according to the Ministry of Health, Labor and Welfare.

In Japan the precautionary suspension remain until at least Tuesday pending the results of an investigation by a group of medical experts.

The ministry reported that three infants under the age of two died within three days of receiving the two vaccine shots, with two of the children also receiving DPT shots for diphtheria, whooping cough and tetanus.

A one year-old died a day after being administered Prevenar and a DPT shot, the ministry said, adding that some of the infants had underlying illnesses.

Prevenar and ActHIB became available in Japan around two years ago.

Authorities decided to suspend them after the four deaths occurred between March 2-4, the ministry said.

"Sanofi Pasteur would like to express its sincere condolences to the families affected by these losses", a spokesman told AFP.

"An investigation is underway to which Sanofi Pasteur intends to fully cooperate with health authorities by providing all data available regarding HIB."

In a statement Pfizer said it was fully cooperating with the ministry's suspension and was in the process of gathering information.

"Our company, taking the safety of patients as its top priority, has studied and assessed accumulated information, including that on causal relationships, with regard to the side effects of all products including Prevenar."

The suspension follows the deaths of two infants in southwest France in late February who had been administered Prevenar.

Health authorities on Thursday said the deaths were not linked to the drug.

In 2009, US firm Wyeth, which was later bought by Pfizer, suspended distribution and quarantined a batch of Prevenar in the Netherlands following reports of the deaths of three infants around the time of vaccination.

Dutch authorities and Wyeth in February 2010 determined there was no correlation between the three deaths and the vaccine injections.

In addition to the four cases, Japan's health ministry said another infant also died in November after receiving his second shot of the ActHIB vaccine, a ministry official said.

Explore further: Merck ends development of Parkinson's disease drug

add to favorites email to friend print save as pdf

Related Stories

Kids' Swine flu shots recalled; not strong enough

Dec 15, 2009

(AP) -- Hundreds of thousands of swine flu shots for children have been recalled because tests indicate the vaccine doses lost some strength, government health officials said Tuesday.

Virus outbreak causes 40 child deaths in China

Apr 10, 2010

(AP) -- A top Chinese leader called for stepped-up research into vaccines and drugs for hand, foot and mouth disease after 40 children died from outbreaks last month, a state news agency said Saturday.

Japan reports bird flu outbreak on quail farm

Feb 27, 2009

An outbreak of bird flu has been reported on a quail farm in central Japan but no animals have died and no humans have been infected, the agriculture ministry said Friday.

Recommended for you

J&J expects 10-plus new drug applications by 2017

14 hours ago

(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...

Glaxo, US partnering to develop new antibiotics

May 22, 2013

GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.

User comments : 0

More news stories

Study: No higher cancer rate at Conn. Pratt plant

(AP)—Researchers examining the incidence of brain cancer at jet engine manufacturer Pratt & Whitney in Connecticut say they have found no statistically significant elevations in the rate of cancer among workers.

Hormone replacement therapy—clarity at last

The British Menopause Society and Women's Health Concern have today released updated guidelines on Hormone Replacement Therapy (HRT) to provide clarity around the role of HRT, the benefits and the risks. The new guidelines ...

Controlling mood through the motions of mitochondria

(Medical Xpress)—Regulating the distribution of power in neurons is done by a system that makes the national electric grid look simple by comparison. Each neuron has several thousand mitochondria confined ...

Spheres can form squares

Everybody who has tried to stack oranges in a box knows that a regular packing of spheres in a flat layer naturally leads to a hexagonal pattern, where each sphere is surrounded by six neighbours in a honeycomb-like ...